Harrow Inc (HROW)

$39.42 -0.03 (-0.08%)
Market Cap 1.46B
Revenue (ttm) 199.61M
Net Income (ttm) -17.48M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE 80.42
Profit Margin -8.76%
Debt to Equity Ratio 0.78
Volume 461,400
Avg Vol 540,014
Day's Range N/A - N/A
Shares Out 37.00M
Stochastic %K 68%
Beta 0.33
Analysts Strong Sell
Price Target $61.69

Company Profile

Harrow, Inc., an eyecare pharmaceutical company, engages in the discovery, development, and commercialization of ophthalmic pharmaceutical products. The company offers ImprimisRx, an ophthalmology-focused compounded medications. It provides IHEEZO, a chloroprocaine hydrochloride ophthalmic gel; ophthalmic solutions, including IOPIDINE, VEVYE, and ZERVIATE; MAXITROL eye drops; ILEVRO and NEVANAC, a non-steroidal and anti-inflammatory eye drop for pain and inflammation associated with cataract sur...

Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Phone: 615 733 4730
Address:
1A Burton Hills Boulevard, Suite 200, Nashville, United States
Fullback
Fullback Sep. 12 at 9:52 PM
$HROW https://x.com/Michigan_Value/status/1966605038014398877?t=gA51y6juJ2Efj4C5IqmQhw&s=09 Wow, big increases in Vevye and Iheezo Q3 25/ Q2 25
2 · Reply
Fullback
Fullback Sep. 12 at 7:44 PM
$HROW Several intra day $40 levels, but we can't hold it....sigh. Investor's day and Q3 report awaits, those are the next possible catalyst I believe. Let's see
1 · Reply
Finnish_boy
Finnish_boy Sep. 12 at 5:57 PM
$HROW VEVYE skyrockets in Q4 when they start investing in
0 · Reply
Finnish_boy
Finnish_boy Sep. 12 at 5:54 PM
$HROW Remember. 15% monthly growth is 50% quarter growth.
1 · Reply
Finnish_boy
Finnish_boy Sep. 12 at 4:28 PM
$HROW Nice catalysts ahead. Investor day 26th Potential acquisition before the investor day Big Iheezo September data on 10th October (look at last year data) Q3 report in November I will buy all the extra shares back before the investor day.
1 · Reply
Fullback
Fullback Sep. 12 at 4:05 PM
$HROW From MVI
1 · Reply
Finnish_boy
Finnish_boy Sep. 12 at 3:55 PM
$HROW Vevye growth 15%, iheezo flat. If Iheezo september big, Q3 of iheezo will be very nice. Looking forward the investor day. I expect some acquisition before that also.
2 · Reply
Finnish_boy
Finnish_boy Sep. 12 at 3:26 PM
$HROW Tarsus price action pretty toxic also.. look at that curve lol New investment idea.. Cipher Mining CIRF. Ceo told that they sign at least one deal this year. Also told that markets havent priced in their AI projects. I almost bought at open but i will buy later. Today +8%.. i always miss.
1 · Reply
StockConsultant
StockConsultant Sep. 12 at 1:31 PM
$HROW Harrow stock, watch for a top of range breakout, target 46 area at https://stockconsultant.com/?HROW
0 · Reply
Bondra
Bondra Sep. 12 at 1:10 PM
$HROW @Finnish_boy My wife quieries how you found harrow and where your conviction comes from? Like where it started. Thanks to you we made hella bread 😃
2 · Reply
Latest News on HROW
Harrow: Buy A Blend Of Value And Growth

Sep 12, 2025, 10:57 AM EDT - 12 hours ago

Harrow: Buy A Blend Of Value And Growth

Harrow: A Classical GARP Stock

Sep 9, 2025, 1:11 PM EDT - 3 days ago

Harrow: A Classical GARP Stock

Harrow Announces Pricing of $250.0 Million Offering of Senior Unsecured Notes Due 2030

Sep 8, 2025, 5:57 PM EDT - 4 days ago

Harrow Announces Pricing of $250.0 Million Offering of Senior Unsecured Notes Due 2030

Harrow Announces Offering of $250.0 Million Senior Unsecured Notes Due 2030

Sep 8, 2025, 8:00 AM EDT - 4 days ago

Harrow Announces Offering of $250.0 Million Senior Unsecured Notes Due 2030

Harrow's Ambitious Guidance Puts It In The Proving Ground

Aug 14, 2025, 11:09 PM EDT - 4 weeks ago

Harrow's Ambitious Guidance Puts It In The Proving Ground

Harrow: Exciting Times In Store

Aug 13, 2025, 5:39 PM EDT - 4 weeks ago

Harrow: Exciting Times In Store

Harrow, Inc. (HROW) Q2 2025 Earnings Call Transcript

Aug 12, 2025, 2:47 PM EDT - 4 weeks ago

Harrow, Inc. (HROW) Q2 2025 Earnings Call Transcript

Harrow Announces Second-Quarter 2025 Financial Results

Aug 11, 2025, 4:01 PM EDT - 4 weeks ago

Harrow Announces Second-Quarter 2025 Financial Results

Harrow to Present at H.C. Wainwright 5th Annual Ophthalmology Conference

Aug 6, 2025, 7:00 AM EDT - 5 weeks ago

Harrow to Present at H.C. Wainwright 5th Annual Ophthalmology Conference

Harrow To Report Second Quarter 2025 Financial Results After Market Close on August 11, 2025

Jul 29, 2025, 7:00 AM EDT - 6 weeks ago

Harrow To Report Second Quarter 2025 Financial Results After Market Close on August 11, 2025

Harrow Enters into Commercialization Agreement with Samsung Bioepis for Ophthalmology Biosimilars Portfolio in the United States

Jul 17, 2025, 7:00 AM EDT - 2 months ago

Harrow Enters into Commercialization Agreement with Samsung Bioepis for Ophthalmology Biosimilars Portfolio in the United States

Samsung Bioepis Enters into a Partnership with Harrow for Commercialization of Ophthalmology Biosimilars Portfolio in the United States

Jul 17, 2025, 7:00 AM EDT - 2 months ago

Samsung Bioepis Enters into a Partnership with Harrow for Commercialization of Ophthalmology Biosimilars Portfolio in the United States

HROW Investors Have Opportunity to Join Harrow, Inc. Fraud Investigation with the Schall Law Firm

Jul 15, 2025, 10:38 AM EDT - 2 months ago

HROW Investors Have Opportunity to Join Harrow, Inc. Fraud Investigation with the Schall Law Firm

Harrow's Internal $100 Price Target Is Ambitious, But New Bloomberg Data Backs It Up

Jul 11, 2025, 5:47 PM EDT - 2 months ago

Harrow's Internal $100 Price Target Is Ambitious, But New Bloomberg Data Backs It Up

Harrow: Immense Upside Potential

Jul 9, 2025, 2:52 PM EDT - 2 months ago

Harrow: Immense Upside Potential

Harrow Appoints Mike Biega as Vice President of Investor Relations and Communications

Jun 18, 2025, 7:00 AM EDT - 3 months ago

Harrow Appoints Mike Biega as Vice President of Investor Relations and Communications

I Am Swimming In Dividends With +7% Yields

Jun 13, 2025, 8:30 AM EDT - 3 months ago

I Am Swimming In Dividends With +7% Yields

UMH

Harrow Acquires U.S. Commercial Rights to BYQLOVI™ (Clobetasol Propionate Ophthalmic Suspension) 0.05% from Formosa Pharmaceuticals

Jun 9, 2025, 7:00 AM EDT - 3 months ago

Harrow Acquires U.S. Commercial Rights to BYQLOVI™ (Clobetasol Propionate Ophthalmic Suspension) 0.05% from Formosa Pharmaceuticals

Harrow: Epic Growth & Operating Leverage On Full Display

May 28, 2025, 3:20 PM EDT - 3 months ago

Harrow: Epic Growth & Operating Leverage On Full Display

Harrow to Present at Two Investor Conferences in May

May 14, 2025, 7:00 AM EDT - 4 months ago

Harrow to Present at Two Investor Conferences in May

Harrow, Inc. (HROW) Q1 2025 Earnings Call Transcript

May 10, 2025, 6:17 PM EDT - 4 months ago

Harrow, Inc. (HROW) Q1 2025 Earnings Call Transcript

Harrow Announces First-Quarter 2025 Financial Results

May 8, 2025, 4:01 PM EDT - 4 months ago

Harrow Announces First-Quarter 2025 Financial Results

Harrow to Report First Quarter 2025 Financial Results After Market Close on May 8, 2025

May 5, 2025, 7:00 AM EDT - 4 months ago

Harrow to Report First Quarter 2025 Financial Results After Market Close on May 8, 2025

NORDIC GROUP B.V. THROUGH ITS SUBSIDIARY NORDIC PHARMA, INC.

Apr 24, 2025, 10:00 AM EDT - 5 months ago

NORDIC GROUP B.V. THROUGH ITS SUBSIDIARY NORDIC PHARMA, INC.

Harrow Expands VEVYE® Access for All Program to ImprimisRx's Klarity-C Patients

Apr 10, 2025, 7:00 AM EDT - 5 months ago

Harrow Expands VEVYE® Access for All Program to ImprimisRx's Klarity-C Patients

Harrow: When Cheaper Doesn't Mean Attractive (Rating Upgrade)

Mar 29, 2025, 4:30 PM EDT - 5 months ago

Harrow: When Cheaper Doesn't Mean Attractive (Rating Upgrade)

Harrow, Inc. (HROW) Q4 2024 Earnings Conference Call

Mar 28, 2025, 2:00 PM EDT - 6 months ago

Harrow, Inc. (HROW) Q4 2024 Earnings Conference Call

Harrow Inc.: Roll The Dice For Strong Upside Prospects As Earnings Ramp

Mar 28, 2025, 1:39 PM EDT - 6 months ago

Harrow Inc.: Roll The Dice For Strong Upside Prospects As Earnings Ramp

Harrow Announces Fourth-Quarter and Year-End 2024 Audited Financial Results

Mar 27, 2025, 4:01 PM EDT - 6 months ago

Harrow Announces Fourth-Quarter and Year-End 2024 Audited Financial Results

Harrow To Report Fourth Quarter and Audited Year-End 2024 Financial Results After Market Close on March 27, 2025

Mar 27, 2025, 10:45 AM EDT - 6 months ago

Harrow To Report Fourth Quarter and Audited Year-End 2024 Financial Results After Market Close on March 27, 2025

Harrow Announces Transitional Pass-Through Reimbursement Status for TRIESENCE® (Triamcinolone Acetonide Injectable Suspension) 40 mg/mL

Mar 24, 2025, 7:00 AM EDT - 6 months ago

Harrow Announces Transitional Pass-Through Reimbursement Status for TRIESENCE® (Triamcinolone Acetonide Injectable Suspension) 40 mg/mL

Harrow Provides Fourth Quarter and Year-End 2024 Unaudited Preliminary Financial Results and 2025 Revenue Guidance

Mar 17, 2025, 4:01 PM EDT - 6 months ago

Harrow Provides Fourth Quarter and Year-End 2024 Unaudited Preliminary Financial Results and 2025 Revenue Guidance

Harrow Launches VEVYE® Access for All

Mar 17, 2025, 7:00 AM EDT - 6 months ago

Harrow Launches VEVYE® Access for All

Harrow Executes Five-Year Strategic Supply and Development Agreement for TRIESENCE®

Mar 11, 2025, 7:00 AM EDT - 6 months ago

Harrow Executes Five-Year Strategic Supply and Development Agreement for TRIESENCE®

Harrow to Report Fourth Quarter and Year-End 2024 Financial Results After Market Close on March 17, 2025

Mar 3, 2025, 7:15 AM EST - 6 months ago

Harrow to Report Fourth Quarter and Year-End 2024 Financial Results After Market Close on March 17, 2025

Smallcap Eyecare Pharma Company Harrow Health Has Two Major Catalysts For 2025

Mar 1, 2025, 8:50 AM EST - 6 months ago

Smallcap Eyecare Pharma Company Harrow Health Has Two Major Catalysts For 2025

Harrow Partners with Cencora to Launch “Harrow Cares” Program, Making IHEEZO® and TRIESENCE® More Accessible and Affordable for Retina Specialists and Their Patients

Jan 27, 2025, 7:30 AM EST - 8 months ago

Harrow Partners with Cencora to Launch “Harrow Cares” Program, Making IHEEZO® and TRIESENCE® More Accessible and Affordable for Retina Specialists and Their Patients

COR

Harrow Appoints Amir H. Shojaei as Chief Scientific Officer

Jan 7, 2025, 7:00 AM EST - 8 months ago

Harrow Appoints Amir H. Shojaei as Chief Scientific Officer

Those Derisked Baby Bonds Of Harrow, Inc.

Jan 3, 2025, 3:43 PM EST - 9 months ago

Those Derisked Baby Bonds Of Harrow, Inc.

Harrow: The Triesence Relaunch

Dec 14, 2024, 12:09 AM EST - 9 months ago

Harrow: The Triesence Relaunch

Harrow's ImprimisRx Subsidiary Receives $34.9 Million Unanimous Jury Verdict Award in ImprimisRx, LLC v. OSRX, Inc.

Nov 21, 2024, 7:00 AM EST - 10 months ago

Harrow's ImprimisRx Subsidiary Receives $34.9 Million Unanimous Jury Verdict Award in ImprimisRx, LLC v. OSRX, Inc.

Harrow Announces Participation in Upcoming Investor Conferences

Nov 15, 2024, 7:00 AM EST - 10 months ago

Harrow Announces Participation in Upcoming Investor Conferences

Harrow, Inc. (HROW) Q3 2024 Earnings Call Transcript

Nov 14, 2024, 2:56 PM EST - 10 months ago

Harrow, Inc. (HROW) Q3 2024 Earnings Call Transcript

Harrow Announces Third Quarter 2024 Financial Results

Nov 13, 2024, 4:34 PM EST - 10 months ago

Harrow Announces Third Quarter 2024 Financial Results

Harrow Launches Access and Affordability Program with Price Reductions for Branded Products

Nov 13, 2024, 7:00 AM EST - 10 months ago

Harrow Launches Access and Affordability Program with Price Reductions for Branded Products

GDRX

Harrow Announces Market Access Wins for VEVYE®

Nov 12, 2024, 7:00 AM EST - 10 months ago

Harrow Announces Market Access Wins for VEVYE®

Harrow: VEVYE And Its Impact On The DED Market

Nov 11, 2024, 6:37 AM EST - 10 months ago

Harrow: VEVYE And Its Impact On The DED Market

Fullback
Fullback Sep. 12 at 9:52 PM
$HROW https://x.com/Michigan_Value/status/1966605038014398877?t=gA51y6juJ2Efj4C5IqmQhw&s=09 Wow, big increases in Vevye and Iheezo Q3 25/ Q2 25
2 · Reply
Fullback
Fullback Sep. 12 at 7:44 PM
$HROW Several intra day $40 levels, but we can't hold it....sigh. Investor's day and Q3 report awaits, those are the next possible catalyst I believe. Let's see
1 · Reply
Finnish_boy
Finnish_boy Sep. 12 at 5:57 PM
$HROW VEVYE skyrockets in Q4 when they start investing in
0 · Reply
Finnish_boy
Finnish_boy Sep. 12 at 5:54 PM
$HROW Remember. 15% monthly growth is 50% quarter growth.
1 · Reply
Finnish_boy
Finnish_boy Sep. 12 at 4:28 PM
$HROW Nice catalysts ahead. Investor day 26th Potential acquisition before the investor day Big Iheezo September data on 10th October (look at last year data) Q3 report in November I will buy all the extra shares back before the investor day.
1 · Reply
Fullback
Fullback Sep. 12 at 4:05 PM
$HROW From MVI
1 · Reply
Finnish_boy
Finnish_boy Sep. 12 at 3:55 PM
$HROW Vevye growth 15%, iheezo flat. If Iheezo september big, Q3 of iheezo will be very nice. Looking forward the investor day. I expect some acquisition before that also.
2 · Reply
Finnish_boy
Finnish_boy Sep. 12 at 3:26 PM
$HROW Tarsus price action pretty toxic also.. look at that curve lol New investment idea.. Cipher Mining CIRF. Ceo told that they sign at least one deal this year. Also told that markets havent priced in their AI projects. I almost bought at open but i will buy later. Today +8%.. i always miss.
1 · Reply
StockConsultant
StockConsultant Sep. 12 at 1:31 PM
$HROW Harrow stock, watch for a top of range breakout, target 46 area at https://stockconsultant.com/?HROW
0 · Reply
Bondra
Bondra Sep. 12 at 1:10 PM
$HROW @Finnish_boy My wife quieries how you found harrow and where your conviction comes from? Like where it started. Thanks to you we made hella bread 😃
2 · Reply
Finnish_boy
Finnish_boy Sep. 12 at 11:48 AM
$HROW "And by the way, it's the biggest thing that we have. I would say it ranks meaningfully higher in terms of the market opportunity than even Vevye for sure." Yes pretty clear.
1 · Reply
Finnish_boy
Finnish_boy Sep. 12 at 11:37 AM
$HROW MELT-300 is diamond, especially for Harrow when they replace MKO Melt. "it's going to be a big product" "It's patented not only domestically, it's patented internationally" "it creates sort of as much of a no-brainer commercial launch as you could possibly have."
0 · Reply
Finnish_boy
Finnish_boy Sep. 12 at 8:59 AM
$HROW Like how big this effect will be? Time will tell: "And so if we had an FDA approved product, we think hopefully the unit volumes would increase marked"
1 · Reply
Finnish_boy
Finnish_boy Sep. 12 at 8:57 AM
$HROW Safemargin has good point.. maybe i underestimate the effect of pass through status / j-code of MELT-300. But i will wait Baum comments.
0 · Reply
Finnish_boy
Finnish_boy Sep. 12 at 7:16 AM
$HROW MELT acquisition no-brainer. We get $100M product starting in 2027. Then multi-billion revenue opportunity starting 2030. And then we will have MELT-210 and MELT-300. They are just Midazolam and Ketamine with Zydia technology. Likely loads of competition here. Huge deal at the end.
1 · Reply
Finnish_boy
Finnish_boy Sep. 11 at 10:58 PM
$HROW Okay, MELT-300 in cataracts maybe 120-140m, not 80-90m what i told.. time will tell. "And depending on how the pricing goes, it could deliver just replacing the compounded revenue with the branded revenue, about $100,000,000 of annual sales. And that's really for a compounded medication. It is not easy to sell non FDA approved products. And so if we had an FDA approved product, we think hopefully the unit volumes would increase markedly"
1 · Reply
Finnish_boy
Finnish_boy Sep. 11 at 9:50 PM
$HROW MELT-300 total TAM 50 million units. Using $300 price (you can use other number), total TAM in dollars 15B. Melt-300 has potential to be 1.5-2B drug for sure🤑 but yea, launch far away.. but something to wait
3 · Reply
Fullback
Fullback Sep. 11 at 8:36 PM
$HROW As far as Melt 300, how can avoiding an IV via a non opiod sublingual dose not be a huge winner. Im IV adverse and I'd prefer Melt 300 no question. I just don't understand the apathy by some investors on it's potential.
3 · Reply
Finnish_boy
Finnish_boy Sep. 11 at 7:54 PM
$HROW Refi didnt have much impact on SP. It was priced in likely. Lets see if big boys buy some shares tomorrow if IHEEZO big number.
1 · Reply
Finnish_boy
Finnish_boy Sep. 11 at 7:23 PM
$HROW
1 · Reply
Finnish_boy
Finnish_boy Sep. 11 at 5:53 PM
$HROW XBI start to look nice. MAs in a right order and 200MA turning up.. XBI likes rate cuts.. at least 2 cuts this year.. i expect also rotation into healthcare / bio stocks.. bodes very well for Harrow also.
0 · Reply
Finnish_boy
Finnish_boy Sep. 11 at 4:54 PM
$HROW Little boost for SP
1 · Reply